Meeting NewsVideo

VIDEO: Neurotech progresses in MacTel, glaucoma treatment pipeline

CHICAGO ― At the Ophthalmology Innovation Summit at AAO, Richard Small, CPA, CEO of Neurotech Pharmaceuticals, discusses the phase 3 progress of encapsulated cell therapy, or ECP, for the treatment of macular telangiectasia or MacTel, as well as their progress in treating glaucoma.

CHICAGO ― At the Ophthalmology Innovation Summit at AAO, Richard Small, CPA, CEO of Neurotech Pharmaceuticals, discusses the phase 3 progress of encapsulated cell therapy, or ECP, for the treatment of macular telangiectasia or MacTel, as well as their progress in treating glaucoma.

    See more from Ophthalmology Innovation Summit